8 research outputs found
Towards early inclusion of children in tuberculosis drugs trials : a consensus statement
Children younger than 18 years account for a substantial proportion of patients with tuberculosis worldwide. Available
treatments for paediatric drug-susceptible and drug-resistant tuberculosis, albeit generally eff ective, are hampered by
high pill burden, long duration of treatment, coexistent toxic eff ects, and an overall scarcity of suitable child-friendly
formulations. Several new drugs and regimens with promising activity against both drug-susceptible and drug-resistant
strains have entered clinical development and are either in various phases of clinical investigation or have received
marketing authorisation for adults; however, none have data on their use in children. This consensus statement,
generated from an international panel of opinion leaders on childhood tuberculosis and incorporating reviews of
published literature from January, 2004, to May, 2014, addressed four key questions: what drugs or regimens should be
prioritised for clinical trials in children? Which populations of children are high priorities for study? When can
phase 1 or 2 studies be initiated in children? What are the relevant elements of clinical trial design? The consensus
panel found that children can be included in studies at the early phases of drug development and should be an integral
part of the clinical development plan, rather than studied after regulatory approval in adults is obtained.National Institute of Allergy and Infectious Diseases and National Institute of Health.Department of Health and Human Services.http://www.thelancet.com/infection2016-06-30hb201
Characterization and Dynamics of Middle Ear Fluid and Nasopharyngeal Isolates of Streptococcus pneumoniae from 12 Children Treated with Levofloxacinâ–¿
Children who had acute otitis media and were treated with levofloxacin were assessed for the emergence of fluoroquinolone-resistant Streptococcus pneumoniae. Nasopharynx cultures were obtained from patients at the entry to and during levofloxacin therapy. All nasopharynx isolates (n = 59) from 12 children were levofloxacin susceptible without parC/E or gyrA/B mutations. Pneumococcal nasopharynx persistence was not associated with levofloxacin resistance
Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed clinical case definitions for classification of Intrathoracic Tuberculosis Disease. Consensus from an expert panel
To access this article, click on "Additional Links"There is a critical need for improved diagnosis of tuberculosis in children, particularly in young children with intrathoracic disease as this represents the most common type of tuberculosis in children and the greatest diagnostic challenge. There is also a need for standardized clinical case definitions for the evaluation of diagnostics in prospective clinical research studies that include children in whom tuberculosis is suspected but not confirmed by culture of Mycobacterium tuberculosis. A panel representing a wide range of expertise and child tuberculosis research experience aimed to develop standardized clinical research case definitions for intrathoracic tuberculosis in children to enable harmonized evaluation of new tuberculosis diagnostic technologies in pediatric populations. Draft definitions and statements were proposed and circulated widely for feedback. An expert panel then considered each of the proposed definitions and statements relating to clinical definitions. Formal group consensus rules were established and consensus was reached for each statement. The definitions presented in this article are intended for use in clinical research to evaluate diagnostic assays and not for individual patient diagnosis or treatment decisions. A complementary article addresses methodological issues to consider for research of diagnostics in children with suspected tuberculosis